CMS NCD 19 Update: What Billing Teams Need to Know About Induced Lesions of Nerve Tracts Coverage

CMS has issued a modification to National Coverage Determination (NCD) 19, which governs Medicare coverage for surgically induced lesions of nerve tracts—a category of procedures used to ablate nerve tissue for pain control. This update affects how Medicare Administrative Contractors (MACs) evaluate medical necessity for denervation procedures, including rhizolysis, chemical nerve destruction, and radio-frequency lesion creation. If your practice performs or bills for these procedures in pain management, neurosurgery, or orthopedic surgery, this policy warrants your attention now.

What CMS NCD 19 Covers: Medicare Policy on Nerve Tract Ablation Procedures

The Centers for Medicare & Medicaid Services, the federal agency that administers Medicare, maintains NCD 19 as the governing coverage policy for induced lesions of nerve tracts under the Physicians' Services benefit category. This policy applies specifically to procedures that destroy nerve tissue—as opposed to stimulate it—for the purpose of chronic or acute pain control.

Under the modified NCD 19, Medicare will cover denervation procedures in selected cases when the MAC's medical staff concurs that the procedure is medically appropriate. That concurrence requirement is not optional—it is a condition of coverage. Billing teams that treat this as a box-checking exercise rather than a clinical documentation requirement risk claim denial.

The policy explicitly identifies two primary clinical indications that support medical necessity:

• Terminal cancer pain — Patients with chronic or acute pain arising from malignancy
• Lumbar degenerative arthritis — Patients with chronic pain from degenerative joint disease of the lumbar spine

These are listed as the primary indications, not the only possible indications. However, documentation supporting any other diagnosis will need to be especially robust to withstand MAC review.

Covered Procedure Types Under CMS NCD 19

NCD 19 identifies three distinct methods by which induced lesions of nerve tracts may be created, all of which are eligible for Medicare program payment when medical necessity criteria are met:

1. Rhizolysis — Surgical cutting of the nerve
2. Chemical nerve destruction — Use of neurolytic agents to chemically ablate nerve tissue
3. Radio-frequency lesion creation (electrocautery) — High-frequency electrical current used to create a thermal lesion on the nerve

All three approaches fall under the umbrella of denervation procedures. The common clinical thread is that nerve fibers are ablated—permanently disrupted—rather than modulated or stimulated.

This is a critical distinction CMS draws explicitly in the policy, and it has direct implications for how you code and document these cases.

How CMS Distinguishes Nerve Ablation from Neurostimulation

One of the most operationally important clarifications in NCD 19 is how CMS differentiates these denervation procedures from neuromodulation or neurostimulation. The policy is explicit: procedures covered under NCD 19 differ from those using implanted electrodes and associated electronic equipment to control pain.

In neurostimulation, nerve fibers are stimulated, not destroyed, and the patient requires ongoing electronic equipment after the procedure. In the denervation procedures covered by NCD 19, nerve fibers are ablated and no electronic equipment is required post-operatively.

This distinction matters for billing because CMS has separate coverage policy frameworks for spinal cord stimulation and implanted peripheral nerve stimulators. Misrouting a claim under the wrong policy—or allowing documentation to blur the line between ablation and stimulation—creates unnecessary denial risk and audit exposure. Make sure your documentation clearly reflects the ablative nature of the procedure.

Medical Necessity Criteria for CMS NCD 19 Coverage

Based on the NCD 19 policy as modified effective March 12, 2026, Medicare coverage for induced lesions of nerve tracts requires the following conditions to be met:

That last point deserves emphasis. MAC concurrence is a structural requirement embedded in this NCD. Your billing team should confirm whether your MAC has a specific mechanism for documenting this concurrence—whether through prior authorization, a clinical review process, or documentation standards outlined in a Local Coverage Determination (LCD). Check your MAC's website for any associated LCDs or articles that supplement NCD 19 in your jurisdiction.

Affected Codes

The current version of NCD 19 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes within the policy document. No codes are enumerated in the policy data for this update.

This absence of code-level guidance shifts more responsibility to your clinical documentation and to MAC-level policies in your region. Revenue cycle teams should:

• Cross-reference this NCD against any applicable MAC LCDs for nerve ablation or denervation in their jurisdiction
• Identify the CPT codes your practice currently uses for rhizolysis, chemical neurolysis, and radio-frequency ablation procedures, and map them against MAC coverage articles
• Confirm with your MAC whether any code-specific guidance applies locally

What Your Billing Team Should Do